Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity.

Biochemical and biophysical research communications - 8 Apr 2011

Tada Noriko, Horibe Tomohisa, Haramoto Mari, Ohara Koji, Kohno Masayuki, Kawakami Koji

Abstract excerpt

We previously reported that novel targeted "hybrid peptide" in which epidermal growth factor receptor (EGFR) binding peptide was conjugated with lytic-type peptide had selective cytotoxic activity to EGFR expressing cancer cell lines, and in vivo analysis revealed that this EGFR-lytic peptide displayed significant antitumor activity in a xenograft model of human breast cancer which was resistant to tyrosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Arginine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Histidine

Share to Mice, Nude

Share to Peptides

Share to Recombinant Fusion Proteins

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 21396910
DOI: 10.1016/j.bbrc.2011.03.030

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity.PMID 21396910Read ↗

Development of a human epidermal growth factor derivative with EGFR-blocking and depleted biological activities: A comparative in vitro study using EGFR-positive breast cancer cells.Semantic proximity Read ↗

An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation.Semantic proximity Read ↗

Molecular docking of the pentapeptide derived from rice bran protein as anticancer agent inhibiting both receptor and non-receptor tyrosine kinases.Semantic proximity Read ↗

An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacySemantic proximity Read ↗

Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule.Semantic proximity Read ↗

Identification of amino acid residues in PEPHC1 important for binding to the tumor-specific receptor EGFRvIII.Semantic proximity Read ↗

A Tumor-Penetrating Peptide Modification Enhances the Antitumor Activity of Thymosin Alpha 1Semantic proximity Read ↗

A lysine-free mutant of epidermal growth factor as targeting moiety of a targeted toxin.Semantic proximity Read ↗

A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2.Semantic proximity Read ↗

A Novel Dual-labeled Peptide for Multimodal Imaging of EGFR with L858R Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.